New Test Could Predict Response to Chemotherapy in Lung Cancer Patients

Treatment & Doctors
Reading Time: 3 mins
Publication Date: 10/31/2012
Fact Checked
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Reviewed is the nation’s most trusted mesothelioma resource

The Mesothelioma Center at has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.

Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.

More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.

About The Mesothelioma Center at

  • Assisting mesothelioma patients and their loved ones since 2006.
  • Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
  • A+ rating from the Better Business Bureau.
  • 5-star reviewed mesothelioma and support organization.
Learn More About Us


"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."
Mesothelioma patient’s daughter
  • Google Review Rating
  • BBB Review Rating

How to Cite’s Article


Franz, F. (2022, November 23). New Test Could Predict Response to Chemotherapy in Lung Cancer Patients. Retrieved December 5, 2022, from


Franz, Faith. "New Test Could Predict Response to Chemotherapy in Lung Cancer Patients.", 23 Nov 2022,


Franz, Faith. "New Test Could Predict Response to Chemotherapy in Lung Cancer Patients." Last modified November 23, 2022.

What if there was a way to find out whether or not you’d respond to treatment before you actually agreed to do it?

For patients with gynecological cancer, it’s already a reality.

Patients with non-small cell lung cancer may be next.

ChemoFx — a test produced by Precision Therapeutics — evaluates tissue samples to determine which, if any, chemotherapy drugs will cause a response. It can predict whether a full course of chemotherapy is more likely to produce a full response, an intermediate response or no response at all.

Even though the test is only approved for use with ovarian, cervical and endometrial cancers, a new study indicates that with a few modifications, it may also accurately predict chemotherapy response in lung cancer specimens.

ChemoFx Can Evaluate Up to a Dozen Drug Combinations

For a ChemoFx analysis, doctors take two small core needle biopsy samples or two samples of pleural fluid. They then mail these samples to a laboratory, where they are mixed with reactive chemicals and analyzed.

The test can evaluate up to 12 drugs or drug combinations at one time. Results rank each drug from most to least likely to produce a full result.

In most clinical trials, the ChemoFx results correlated with patient’s progression-free intervals. Patients treated with a drug from the responsive category had an overall survival that was more than 2.5 times longer than patients treated with an unresponsive drug.

Doctors have used ChemoFx in a number of different clinical scenarios, including:

  • When a patient has too high of a toxicity risk with the chemotherapy drug most commonly used for their type of cancer.
  • When the patient does not respond to initial treatment.
  • When there is no established protocol for the patient’s specific tumor type.
  • When patients need second-line chemotherapy for a recurrent tumor.

Patients typically get their results quickly enough to not delay treatment.

Adapting ChemoFx for Lung Cancer

In the non-small cell lung cancer trial, researchers modified the drug response marker to evaluate pemetrexed — one of the most common lung cancer chemotherapy drugs.

Researchers obtained a total of 65 specimens. They then added epidermal growth factor and RPMI to the samples to make them grow the way they would in the human body.

The test predicted that 84.6 percent of the samples would not respond to the pemetrexed. Only 6.2 percent of the specimens were fully responsive, while 9.2 percent were intermediately responsive.

The full study will appear in the January 2013 issue of Landes Bioscience.

How ChemoFx Could Optimize Lung Cancer Treatment

Currently, to choose a chemotherapy regimen for a lung cancer patient, oncologists evaluate the patient’s age, overall health, cancer stage and specific diagnosis. They then choose the drug that is the current standard of treatment for patients with the same condition.

However, these factors do not always accurately predict the patient’s response to treatment. At best, it’s an educated guess. Many patients end up trying costly and aggressive chemotherapy regimens that ultimately do not shrink their tumors.

If ChemoFx is successfully adapted for non-small cell lung cancer, patients could reduce their risk of wasting time on ineffective therapies.

The pre-treatment analysis could also prevent patients from developing debilitating side effects from treatments that do not ultimately improve their condition.

Medically Reviewed by Top Mesothelioma Doctors
Free Mesothelioma Guide